Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2022-01-04 00:00:00 ET · period of report 2022-01-03 · accession 0001628280-22-000182 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-04 | 2022-01-03 | AUPH | Hagan Joseph P | Dir | M - OptEx | $5.08 | +40.0K | 43.5K | +1,143% | +$203.2K |
| DM | 2022-01-04 | 2022-01-03 | AUPH | Hagan Joseph P | Dir | S - Sale+OE | $22.59 | -40.0K | 3,500 | -92% | -$903.7K |
| D | 2022-01-04 | 2022-01-03 | AUPH | Hagan Joseph P | Dir | M - OptEx | $0.00 | -40.0K | 10.0K | -80% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-03 | M | A | 40,000 | $5.08 | 43,500 | D | — | — | (F1) Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. |
| 2 | Common | Common Stock | 2022-01-03 | S | D | 39,366 | $22.58 | 4,134 | D | — | — | (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.27 to $23.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2022-01-03 | S | D | 634 | $23.29 | 3,500 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2022-01-03 | M | D | 40,000 | $0.00 | 10,000 | D | $5.08 · — to 2028-02-08 | 40,000 Common Stock | (F1) Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. (F4) The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. |